HLB Pharmaceutical（A047920）株式概要製薬会社HLB Pharmaceutical Co., Ltd.は韓国でペプチド医薬品の研究開発を行っている。 詳細A047920 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績2/6財務の健全性4/6配当金0/6報酬過去 1 年間で収益は65.2%増加しましたリスク分析利益率(1.6%)は昨年より低い(2.7%) 意味のある時価総額がありません ( ₩120B )すべてのリスクチェックを見るA047920 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,774 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG491,774 investors already sharing narrativesYour Fair Value₩Current Price₩8.57k40.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b237b2016201920222025202620282031Revenue ₩236.6bEarnings ₩3.7bAdvancedSet Fair ValueView all narrativesHLB Pharmaceutical Co., Ltd. 競合他社Ahn-Gook PharmaceuticalSymbol: KOSDAQ:A001540Market cap: ₩127.3bHigh Tech PharmSymbol: KOSDAQ:A106190Market cap: ₩127.4bKyung Dong PharmaceuticalSymbol: KOSDAQ:A011040Market cap: ₩134.6bIlsung IsSymbol: KOSE:A003120Market cap: ₩140.8b価格と性能株価の高値、安値、推移の概要HLB Pharmaceutical過去の株価現在の株価₩8,570.0052週高値₩22,250.0052週安値₩8,570.00ベータ0.201ヶ月の変化-21.81%3ヶ月変化-52.23%1年変化-52.55%3年間の変化-30.33%5年間の変化-40.69%IPOからの変化7.12%最新ニュースValuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to ₩8,570, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 30% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩13,140, the stock trades at a trailing P/E ratio of 49.6x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 2.3% over the past three years.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩151.7b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩151.7b market cap, or US$97.2m).New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.6% Last year net profit margin: 2.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩13,490, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 11% over the past three years.お知らせ • May 15HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion.HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,762,332 Price\Range: KRW 11150 Discount Per Security: KRW 111.5 Transaction Features: Rights Offering最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to ₩8,570, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 30% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩13,140, the stock trades at a trailing P/E ratio of 49.6x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 2.3% over the past three years.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩151.7b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩151.7b market cap, or US$97.2m).New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.6% Last year net profit margin: 2.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩13,490, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 11% over the past three years.お知らせ • May 15HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion.HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,762,332 Price\Range: KRW 11150 Discount Per Security: KRW 111.5 Transaction Features: Rights OfferingValuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩19,410, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.分析記事 • Mar 30Investors Shouldn't Be Too Comfortable With HLB Pharmaceutical's (KOSDAQ:047920) EarningsDespite posting some strong earnings, the market for HLB Pharmaceutical Co., Ltd.'s ( KOSDAQ:047920 ) stock hasn't...お知らせ • Mar 04HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 27, gyeonggang-ro, gyeonggi-do, namyangju South KoreaNew Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change).お知らせ • May 09HLB Pharmaceutical Co., Ltd. announced that it has received KRW 19.00000452 billion in funding from HLB Life Science Co., Ltd.On May 8, 2025, HLB Pharmaceutical Co., Ltd. closed the transaction.お知らせ • Apr 25+ 1 more updateHLB Pharmaceutical Co., Ltd. announced that it expects to receive KRW 19.00000452 billion in funding from HLB Life Science Co., Ltd.HLB Pharmaceutical Co., Ltd announced a Private placement to issue 976,362 Common Shares at KRW 19,460 per common share for aggregate gross Proceeds of KRW 19,000,004,520 on April 24, 2025. The Transaction will include participation from new Investor HLB Life Sciences Co., Ltd. The securities issued will have a lockup period of 1 year. The transaction is expected to close on May 8, 2025.お知らせ • Feb 26HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2025HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 27, gyeonggang-ro, gyeonggi-do, namyangju South KoreaNew Risk • Nov 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Mar 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change).New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Internal Director Yong-Dong Cho was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Aug 11+ 1 more updateHLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.On August 10, 2022, HLB Pharmaceutical Co., Ltd closed the transaction.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Internal Director Yong-Dong Cho was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 14HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in fundingOn March 12, 2021, HLB Pharmaceutical Co., Ltd (KOSDAQ:A047920) closed the transaction.お知らせ • Feb 11HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in fundingHLB Pharmaceutical Co., Ltd (KOSDAQ:A047920) announced a private placement of series 14 non-guaranteed private equity convertible bonds for the gross proceeds of KRW 13,200,000,000 on February 10, 2021. The transaction will include participation from new investor, Faith 1 Fund. The bonds carry coupon rate of 0% and surface interest rate of 0% and will mature on March 12, 2024. The bonds are 100% convertible into 817,236 common shares representing 3.66% stake at a conversion price of KRW 16,152 per share. The conversion period will start on March 12, 2022 and end on February 12, 2024. The subscription date is February 10, 2021 and payment date is March 12, 2021. The transaction was approved by board of directors of the company.分析記事 • Dec 28Is HLB Pharmaceutical Co., Ltd's (KOSDAQ:047920) Shareholder Ownership Skewed Towards Insiders?The big shareholder groups in HLB Pharmaceutical Co., Ltd ( KOSDAQ:047920 ) have power over the company. Large...お知らせ • Oct 20+ 1 more updateMediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from EBEST Investment & Securities Co., Ltd.On October 19, 2020, Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) closed the transaction.お知らせ • Sep 11Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd.On September 10, 2020, Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) closed the transaction. The company issued 4,154,511 shares for gross proceeds of KRW 18,632,981,835 in its second and final tranche. The company received KRW 48,632,978,215 in the transaction.お知らせ • Sep 01Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from HLB Co., Ltd. and other investorMediforum Pharmaceutical Incorporation (KOSDAQ:A047920) announced a private placement of series 12 and series 13 unregistered non guaranteed private convertible bond for the gross proceeds of KRW 10,000,000,000 each for aggregate gross proceeds of KRW 20,000,000,000 on August 31, 2020. The transaction will include participation from new investor HLB Co., Ltd. (KOSDAQ:A028300) for series 12 bonds and new investor Jaram Fund 1 for series 13 bonds. The bonds carry coupon rate of 1% and surface interest rate of 1% and will mature on October 30, 2023. The series 12 and series 13 bonds are 100% convertible into 1,494,992 common shares each at a conversion price of KRW 6,689 per share. The conversion period will start on October 30, 2021 and end on September 30, 2023. The subscription date is August 31, 2020 and payment date is October 30, 2020. The transaction was approved by board of directors of the company.お知らせ • Jul 02Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from Ibest Investment Company Ltd., Hanyang Securities Co. Ltd., Investment Arm, EBEST Investment & Securities Co., Ltd.Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) announced a private placement of series 11 unregistered coupon non guaranteed private convertible bond for the gross proceeds of KRW 20,000,000,000 on April 27, 2020. The transaction will include participation from Ibest Investment Company Ltd. and Hanyang Securities Co. Ltd., Investment Arm for KRW 10,000,000,000 each. The bonds carry coupon rate of 1% and surface interest rate of 1% and will mature on June 29, 2023. The bonds are 100% convertible into 3,556,188 registered common shares of the company at conversion price of KRW 5,624 per share. The conversion period will start on June 29, 2021 and end on May 29, 2023. The payment date is June 29, 2020. The transaction was approved by board of directors of the company.株主還元A047920KR PharmaceuticalsKR 市場7D-27.5%-5.2%-7.3%1Y-52.5%-7.6%123.0%株主還元を見る業界別リターン: A047920過去 1 年間で-7.6 % の収益を上げたKR Pharmaceuticals業界を下回りました。リターン対市場: A047920は、過去 1 年間で123 % のリターンを上げたKR市場を下回りました。価格変動Is A047920's price volatile compared to industry and market?A047920 volatilityA047920 Average Weekly Movement12.0%Pharmaceuticals Industry Average Movement6.7%Market Average Movement9.4%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%安定した株価: A047920 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A047920の 週次ボラティリティ ( 12% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1998n/aJae-Hyung Parkwww.hlbpharma.co.krHLB Pharmaceutical Co., Ltd.は製薬会社で、韓国でペプチド医薬品の研究開発を行っている。同社は骨格筋弛緩剤、精神安定剤、抗ヒスタミン剤、降圧剤、鎮痛剤、鎮痒剤、収斂剤、抗炎症剤、消化器系薬剤、代謝性薬剤、眼科用薬剤、局所麻酔剤、抗動脈硬化剤、去痰剤、解熱剤、鎮痛剤、抗糖尿病剤、化学療法剤、消化性潰瘍剤中枢神経系薬剤、抗生物質、消化剤、制酸剤、歯科用薬剤、マルチビタミン剤、寄生性皮膚疾患用薬剤、皮膚科用薬剤、泌尿生殖器官用薬剤、アミノ酸剤、鎮咳剤、粘液溶解剤、駆虫剤、止瀉剤、循環器官用薬剤、ビタミン剤、皮膚軟化剤、痔疾用薬剤、肝臓疾患用薬剤。また、脊髄小脳変性症による運動失調の治療薬としてCTT-004を開発中であり、CMOサービスも提供している。旧社名はメディフォルムファーマシューティカル株式会社で、2020年10月にHLBファーマシューティカル株式会社に社名変更した。HLB Pharmaceutical Co., Ltd.は1998年に設立され、韓国の南楊州市に本社を置いています。もっと見るHLB Pharmaceutical Co., Ltd. 基礎のまとめHLB Pharmaceutical の収益と売上を時価総額と比較するとどうか。A047920 基礎統計学時価総額₩120.34b収益（TTM）₩3.72b売上高(TTM)₩236.59b32.3xPER（株価収益率0.5xP/SレシオA047920 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A047920 損益計算書（TTM）収益₩236.59b売上原価₩124.29b売上総利益₩112.30bその他の費用₩108.57b収益₩3.72b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）265.16グロス・マージン47.47%純利益率1.57%有利子負債／自己資本比率9.9%A047920 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 11:45終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HLB Pharmaceutical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to ₩8,570, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 30% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩13,140, the stock trades at a trailing P/E ratio of 49.6x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 2.3% over the past three years.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩151.7b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩151.7b market cap, or US$97.2m).
New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.6% Last year net profit margin: 2.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩13,490, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 11% over the past three years.
お知らせ • May 15HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion.HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,762,332 Price\Range: KRW 11150 Discount Per Security: KRW 111.5 Transaction Features: Rights Offering
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to ₩8,570, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 10x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 30% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩13,140, the stock trades at a trailing P/E ratio of 49.6x. Average trailing P/E is 11x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 2.3% over the past three years.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩151.7b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₩151.7b market cap, or US$97.2m).
New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.6% Last year net profit margin: 2.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩13,490, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 11% over the past three years.
お知らせ • May 15HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion.HLB Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 120.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,762,332 Price\Range: KRW 11150 Discount Per Security: KRW 111.5 Transaction Features: Rights Offering
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩19,410, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.
分析記事 • Mar 30Investors Shouldn't Be Too Comfortable With HLB Pharmaceutical's (KOSDAQ:047920) EarningsDespite posting some strong earnings, the market for HLB Pharmaceutical Co., Ltd.'s ( KOSDAQ:047920 ) stock hasn't...
お知らせ • Mar 04HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 27, gyeonggang-ro, gyeonggi-do, namyangju South Korea
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change).
お知らせ • May 09HLB Pharmaceutical Co., Ltd. announced that it has received KRW 19.00000452 billion in funding from HLB Life Science Co., Ltd.On May 8, 2025, HLB Pharmaceutical Co., Ltd. closed the transaction.
お知らせ • Apr 25+ 1 more updateHLB Pharmaceutical Co., Ltd. announced that it expects to receive KRW 19.00000452 billion in funding from HLB Life Science Co., Ltd.HLB Pharmaceutical Co., Ltd announced a Private placement to issue 976,362 Common Shares at KRW 19,460 per common share for aggregate gross Proceeds of KRW 19,000,004,520 on April 24, 2025. The Transaction will include participation from new Investor HLB Life Sciences Co., Ltd. The securities issued will have a lockup period of 1 year. The transaction is expected to close on May 8, 2025.
お知らせ • Feb 26HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2025HLB Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 27, gyeonggang-ro, gyeonggi-do, namyangju South Korea
New Risk • Nov 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Mar 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change).
New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2019 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Internal Director Yong-Dong Cho was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Aug 11+ 1 more updateHLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.On August 10, 2022, HLB Pharmaceutical Co., Ltd closed the transaction.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Internal Director Yong-Dong Cho was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 14HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in fundingOn March 12, 2021, HLB Pharmaceutical Co., Ltd (KOSDAQ:A047920) closed the transaction.
お知らせ • Feb 11HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in fundingHLB Pharmaceutical Co., Ltd (KOSDAQ:A047920) announced a private placement of series 14 non-guaranteed private equity convertible bonds for the gross proceeds of KRW 13,200,000,000 on February 10, 2021. The transaction will include participation from new investor, Faith 1 Fund. The bonds carry coupon rate of 0% and surface interest rate of 0% and will mature on March 12, 2024. The bonds are 100% convertible into 817,236 common shares representing 3.66% stake at a conversion price of KRW 16,152 per share. The conversion period will start on March 12, 2022 and end on February 12, 2024. The subscription date is February 10, 2021 and payment date is March 12, 2021. The transaction was approved by board of directors of the company.
分析記事 • Dec 28Is HLB Pharmaceutical Co., Ltd's (KOSDAQ:047920) Shareholder Ownership Skewed Towards Insiders?The big shareholder groups in HLB Pharmaceutical Co., Ltd ( KOSDAQ:047920 ) have power over the company. Large...
お知らせ • Oct 20+ 1 more updateMediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from EBEST Investment & Securities Co., Ltd.On October 19, 2020, Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) closed the transaction.
お知らせ • Sep 11Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd.On September 10, 2020, Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) closed the transaction. The company issued 4,154,511 shares for gross proceeds of KRW 18,632,981,835 in its second and final tranche. The company received KRW 48,632,978,215 in the transaction.
お知らせ • Sep 01Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from HLB Co., Ltd. and other investorMediforum Pharmaceutical Incorporation (KOSDAQ:A047920) announced a private placement of series 12 and series 13 unregistered non guaranteed private convertible bond for the gross proceeds of KRW 10,000,000,000 each for aggregate gross proceeds of KRW 20,000,000,000 on August 31, 2020. The transaction will include participation from new investor HLB Co., Ltd. (KOSDAQ:A028300) for series 12 bonds and new investor Jaram Fund 1 for series 13 bonds. The bonds carry coupon rate of 1% and surface interest rate of 1% and will mature on October 30, 2023. The series 12 and series 13 bonds are 100% convertible into 1,494,992 common shares each at a conversion price of KRW 6,689 per share. The conversion period will start on October 30, 2021 and end on September 30, 2023. The subscription date is August 31, 2020 and payment date is October 30, 2020. The transaction was approved by board of directors of the company.
お知らせ • Jul 02Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from Ibest Investment Company Ltd., Hanyang Securities Co. Ltd., Investment Arm, EBEST Investment & Securities Co., Ltd.Mediforum Pharmaceutical Incorporation (KOSDAQ:A047920) announced a private placement of series 11 unregistered coupon non guaranteed private convertible bond for the gross proceeds of KRW 20,000,000,000 on April 27, 2020. The transaction will include participation from Ibest Investment Company Ltd. and Hanyang Securities Co. Ltd., Investment Arm for KRW 10,000,000,000 each. The bonds carry coupon rate of 1% and surface interest rate of 1% and will mature on June 29, 2023. The bonds are 100% convertible into 3,556,188 registered common shares of the company at conversion price of KRW 5,624 per share. The conversion period will start on June 29, 2021 and end on May 29, 2023. The payment date is June 29, 2020. The transaction was approved by board of directors of the company.
